Teva Pharmaceutical Industries annual operating cash flow
2007
2008
2009
2010
2011
2012
2013
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Teva Pharmaceutical Industries Operating Cash Flow Growth & History (TEVA)
Teva Pharmaceutical Industries's operating cash flow was $1.65B for fiscal 2025.
View full Teva Pharmaceutical Industries company overviewTeva Pharmaceutical Industries annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.65B | $402.0M | +32.24% |
| 2024 | 2024-12-31 | $1.25B | −$121.0M | −8.85% |
| 2023 | 2023-12-31 | $1.37B | −$222.0M | −13.96% |
| 2022 | 2022-12-31 | $1.59B | $792.0M | +99.25% |
| 2021 | 2021-12-31 | $798.0M | −$418.0M | −34.38% |
| 2020 | 2020-12-31 | $1.22B | $468.0M | +62.57% |
| 2019 | 2019-12-31 | $748.0M | −$1.70B | −69.42% |
| 2018 | 2018-12-31 | $2.45B | $221.0M | +9.93% |
| 2017 | 2017-12-31 | $2.23B | −$1.67B | −42.80% |
| 2016 | 2016-12-31 | $3.89B | — | — |
| 2013 | 2013-12-31 | $3.24B | −$1.33B | −29.20% |
| 2012 | 2012-12-31 | $4.57B | $438.0M | +10.60% |
| 2011 | 2011-12-31 | $4.13B | −$2.0M | −0.05% |
| 2010 | 2010-12-31 | $4.14B | $763.0M | +22.62% |
| 2009 | 2009-12-31 | $3.37B | $142.0M | +4.39% |
| 2008 | 2008-12-31 | $3.23B | $1.42B | +78.21% |
| 2007 | 2007-12-31 | $1.81B | — | — |
Teva Pharmaceutical Industries quarterly operating cash flow
Q1.08
Q2.08
Q3.08
Q4.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q1.16
Q2.16
Q3.16
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $411.0M | $184.0M | +81.06% |
| Q1 2026 | 2026-03-31 | −$40.0M | $65.0M | — |
| Q4 2025 | 2025-12-31 | $1.16B | $583.0M | +101.39% |
| Q3 2025 | 2025-09-30 | $369.0M | −$324.0M | −46.75% |
| Q2 2025 | 2025-06-30 | $227.0M | $124.0M | +120.39% |
| Q1 2025 | 2025-03-31 | −$105.0M | $19.0M | — |
| Q4 2024 | 2024-12-31 | $575.0M | −$609.0M | −51.44% |
| Q3 2024 | 2024-09-30 | $693.0M | $688.0M | +13760.00% |
| Q2 2024 | 2024-06-30 | $103.0M | −$221.0M | −68.21% |
| Q1 2024 | 2024-03-31 | −$124.0M | $21.0M | — |
| Q4 2023 | 2023-12-31 | $1.18B | $211.0M | +21.69% |
| Q3 2023 | 2023-09-30 | $5.0M | −$538.0M | −99.08% |
| Q2 2023 | 2023-06-30 | $324.0M | $201.0M | +163.41% |
| Q1 2023 | 2023-03-31 | −$145.0M | −$96.0M | — |
| Q4 2022 | 2022-12-31 | $973.0M | $517.0M | +113.38% |
| Q3 2022 | 2022-09-30 | $543.0M | $14.0M | +2.65% |
| Q2 2022 | 2022-06-30 | $123.0M | −$95.0M | −43.58% |
| Q1 2022 | 2022-03-31 | −$49.0M | $356.0M | — |
| Q4 2021 | 2021-12-31 | $456.0M | $125.0M | +37.76% |
| Q3 2021 | 2021-09-30 | $529.0M | $222.0M | +72.31% |
| Q2 2021 | 2021-06-30 | $218.0M | −$55.0M | −20.15% |
| Q1 2021 | 2021-03-31 | −$405.0M | −$710.0M | — |
| Q4 2020 | 2020-12-31 | $331.0M | −$207.0M | −38.48% |
| Q3 2020 | 2020-09-30 | $307.0M | −$18.0M | −5.54% |
| Q2 2020 | 2020-06-30 | $273.0M | $500.0M | — |
| Q1 2020 | 2020-03-31 | $305.0M | $193.0M | +172.32% |
| Q4 2019 | 2019-12-31 | $538.0M | $171.0M | +46.59% |
| Q3 2019 | 2019-09-30 | $325.0M | −$96.0M | −22.80% |
| Q2 2019 | 2019-06-30 | −$227.0M | −$389.0M | — |
| Q1 2019 | 2019-03-31 | $112.0M | −$1.38B | −92.51% |
| Q4 2018 | 2018-12-31 | $367.0M | −$492.0M | −57.28% |
| Q3 2018 | 2018-09-30 | $421.0M | −$374.0M | −47.04% |
| Q2 2018 | 2018-06-30 | $162.0M | −$273.0M | −62.76% |
| Q1 2018 | 2018-03-31 | $1.50B | $1.36B | +1000.00% |
| Q4 2017 | 2017-12-31 | $859.0M | $769.0M | +854.44% |
| Q3 2017 | 2017-09-30 | $795.0M | −$666.0M | −45.59% |
| Q2 2017 | 2017-06-30 | $435.0M | −$528.0M | −54.83% |
| Q1 2017 | 2017-03-31 | $136.0M | −$1.24B | −90.12% |
| Q4 2016 | 2016-12-31 | $90.0M | — | — |
| Q3 2016 · Sep 30 | 2016-09-30 | $1.46B | $368.0M | +33.67% |
| Q2 2016 · Jun 30 | 2016-06-30 | $963.0M | −$517.0M | −34.93% |
| Q1 2016 · Mar 31 | 2016-03-31 | $1.38B | $22.0M | +1.62% |
| Q3 2016 · Sep 30 | 2015-09-30 | $1.09B | −$331.0M | −23.24% |
| Q2 2016 · Jun 30 | 2015-06-30 | $1.48B | $427.0M | +40.55% |
| Q1 2016 · Mar 31 | 2015-03-31 | $1.35B | $456.0M | +50.78% |
| Q3 2014 | 2014-09-30 | $1.42B | $980.0M | +220.72% |
| Q2 2014 | 2014-06-30 | $1.05B | $178.0M | +20.34% |
| Q1 2014 | 2014-03-31 | $898.0M | −$204.0M | −18.51% |
| Q3 2013 | 2013-09-30 | $444.0M | −$604.0M | −57.63% |
| Q2 2013 | 2013-06-30 | $875.0M | −$316.0M | −26.53% |
| Q1 2013 · Mar 31 | 2013-03-31 | $1.10B | $346.0M | +45.77% |
| Q4 2012 | 2012-12-31 | $1.58B | $149.0M | +10.43% |
| Q3 2012 | 2012-09-30 | $1.05B | $566.0M | +117.43% |
| Q2 2012 | 2012-06-30 | $1.19B | −$133.0M | −10.05% |
| Q1 2012 | 2012-03-31 | $756.0M | −$144.0M | −16.00% |
| Q4 2011 | 2011-12-31 | $1.43B | $326.0M | +29.58% |
| Q3 2011 | 2011-09-30 | $482.0M | −$712.0M | −59.63% |
| Q2 2011 | 2011-06-30 | $1.32B | $370.0M | +38.78% |
| Q1 2011 | 2011-03-31 | $900.0M | $14.0M | +1.58% |
| Q4 2010 | 2010-12-31 | $1.10B | $145.0M | +15.15% |
| Q3 2010 | 2010-09-30 | $1.19B | $169.0M | +16.49% |
| Q2 2010 | 2010-06-30 | $954.0M | $296.0M | +44.98% |
| Q1 2010 | 2010-03-31 | $886.0M | $153.0M | +20.87% |
| Q4 2009 | 2009-12-31 | $957.0M | −$12.0M | −1.24% |
| Q3 2009 | 2009-09-30 | $1.02B | $315.0M | +44.37% |
| Q2 2009 | 2009-06-30 | $658.0M | −$148.0M | −18.36% |
| Q1 2009 | 2009-03-31 | $733.0M | −$13.0M | −1.74% |
| Q4 2008 | 2008-12-31 | $969.0M | — | — |
| Q3 2008 | 2008-09-30 | $710.0M | — | — |
| Q2 2008 | 2008-06-30 | $806.0M | — | — |
| Q1 2008 | 2008-03-31 | $746.0M | — | — |
Teva Pharmaceutical Industries operating cash flow trends
Over the last five fiscal years, Teva Pharmaceutical Industries's operating cash flow increased from $1.22B to $1.65B, a change of $433.0M. The latest reported quarter, Q2 2026, shows $411.0M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teva Pharmaceutical Industries source filings ↗